ORLANDO, FLORIDA—A decision to delay surgery or radiotherapy for early prostate cancer is in the best interests of most patients according to research presented to the 2013 Genitourinary Cancers Symposium by Dr Andrew Loblaw from the Sunnybrook Health Sciences Centre in Toronto. His group’s research has found that the rate of “migration” of Gleason grade — representing disease progression — was gradual: accounting for no more than a third of patients developing a form of the disease requiring treatment within ten years. The remaining patients can be spared the side effects of treatment.
You may also like...
Radiotherapy Triggers Durable Immunotherapy Responsiveness Beyond Radiation Field 24 Aug, 2016 ASCO Audio Journal of Oncology – June 5th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6 4 Jun, 2006 Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue! 6 Oct, 2009 Adjuvant Checkpoint Inhibition Extends Disease-Free and Overall Survival in Patients with Stage III Melanoma 13 Oct, 2016
- Previous story Low risk prostate cancer: less treatment means lower cost, and better patient outcomes
- Next story Androgen blockade: 18 as good as 36 months in radiotherapy-treated prostate cancer
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014